<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02092402</url>
  </required_header>
  <id_info>
    <org_study_id>2013/180</org_study_id>
    <nct_id>NCT02092402</nct_id>
  </id_info>
  <brief_title>Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome</brief_title>
  <official_title>Fecal Microbiota Transplantation in Patients With Irritable Bowel Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Örebro University, Sweden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Örebro University, Sweden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the effect of fecal microbiota transplantation&#xD;
      (FMT) on the symptoms of irritable bowel syndrome (IBS) patients.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS version of the gastrointestinal symptom rating scale (GSRS-IBS)</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal transplantation on IBS patients' visceral perception (Pain scores on the visual analogue scale during barostat procedure)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal transplantation on IBS patients' composition of mucosal microbiota (HITChip analysis)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal transplantation on IBS patients' composition of fecal microbiota (HITChip analysis)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal transplantation on IBS patients' mucosal immune cell composition (lymphocyte fingerprinting using flow cytometry)</measure>
    <time_frame>2 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal microbiota transplantation on the symptoms of IBS patients using the IBS - severity scoring system (IBS-SSS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal microbiota transplantation on the symptoms of IBS patients using the health-related quality of life questionnaire for IBS patients (IBS-QOL)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal microbiota transplantation on the symptoms of IBS patients using the hospital and anxiety depression scale (HADS)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of fecal microbiota transplantation on the general health of IBS patients using the SF-36 survey</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Irritable Bowel Syndrome (IBS)</condition>
  <arm_group>
    <arm_group_label>Fecal transplantation of own stool</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Autologous fecal transplantation (own stool)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fecal transplantation (stool from donor)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Allogeneic fecal transplantation (from donor)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Fecal transplantation</intervention_name>
    <arm_group_label>Fecal transplantation (stool from donor)</arm_group_label>
    <arm_group_label>Fecal transplantation of own stool</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria for patients&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. Fulfilled Rome III diagnostic criteria for IBS, and frequency of IBS pain or&#xD;
             discomfort for at least 2 days a week in the last 12 weeks&#xD;
&#xD;
          3. Age: 18-65 years&#xD;
&#xD;
        Exclusion criteria for patients&#xD;
&#xD;
          1. High proportion of butyrate-producing microbiota in fecal samples&#xD;
&#xD;
          2. Known organic gastrointestinal disease (e.g. IBD)&#xD;
&#xD;
          3. Previous complicated gastrointestinal surgery&#xD;
&#xD;
          4. Non-gastrointestinal malignancy&#xD;
&#xD;
          5. Dementia, severe depression, major psychiatric disorder, or other incapacity for&#xD;
             adequate cooperation&#xD;
&#xD;
          6. Females who are pregnant or breast-feeding&#xD;
&#xD;
          7. Severe endometriosis&#xD;
&#xD;
          8. Antimicrobial treatment 4 weeks prior to first screening visit&#xD;
&#xD;
          9. Antimicrobial prophylaxis (eg. acne, urinary tract infection)&#xD;
&#xD;
         10. Regular consumption of probiotic products 4 weeks prior to randomization&#xD;
&#xD;
         11. Recently (within the last 3 months) diagnosed lactose intolerance&#xD;
&#xD;
         12. Celiac disease&#xD;
&#xD;
         13. Abuse of alcohol or drugs&#xD;
&#xD;
         14. Any clinically significant disease/condition which in the investigator's opinion could&#xD;
             interfere with the results of the trial&#xD;
&#xD;
        Inclusion criteria for donors&#xD;
&#xD;
          1. Signed informed consent&#xD;
&#xD;
          2. High-butyrate producing microbiota in fecal samples&#xD;
&#xD;
          3. Age: 18-65 years&#xD;
&#xD;
        Exclusion criteria for donors&#xD;
&#xD;
          1. Known organic gastrointestinal disease (e.g. IBD, IBS, chronic diarrhea or&#xD;
             constipation)&#xD;
&#xD;
          2. Gastrointestinal malignancy or polyposis&#xD;
&#xD;
          3. History of major gastrointestinal surgery (e.g. gastric bypass)&#xD;
&#xD;
          4. Eosinophilic disorders of the gastrointestinal tract&#xD;
&#xD;
          5. Current communicable disease (e.g. upper respiratory tract infection)&#xD;
&#xD;
          6. Known or high risk of infectious diseases such as HIV, hepatitis A, B or C&#xD;
&#xD;
          7. Non-gastrointestinal malignancy&#xD;
&#xD;
          8. Dementia, severe depression, major psychiatric disorder, or other incapacity for&#xD;
             adequate cooperation&#xD;
&#xD;
          9. Comorbidities such as metabolic syndrome, autoimmune diseases, allergies&#xD;
&#xD;
         10. Chronic pain syndromes (eg. chronic fatigue syndrome, fibromyalgia)&#xD;
&#xD;
         11. Severe or morbid obesity&#xD;
&#xD;
         12. Use of immunosuppressive or chemotherapy agents&#xD;
&#xD;
         13. Antimicrobial treatment or prophylaxis within the last 6 months&#xD;
&#xD;
         14. Females who are pregnant or breast-feeding&#xD;
&#xD;
         15. Known clinically significant abnormal laboratory values&#xD;
&#xD;
         16. Participation in high-risk sexual behaviors&#xD;
&#xD;
         17. Abuse of alcohol or drugs&#xD;
&#xD;
         18. Tattoo or body piercing within the last 6 months&#xD;
&#xD;
         19. Travel to areas with endemic diarrhea during the last 3 months&#xD;
&#xD;
         20. Positive stool testing for C. difficile toxin, ova, parasites, Giarda antigen,&#xD;
             cryptosporidium antigen&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert J Brummer, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Örebro, Department of Gastroenterology and Örebro University, School of Health and Medical Sciences, Faculty of Medicine and Health, Örebro, Sweden</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital Örebro</name>
      <address>
        <city>Örebro</city>
        <zip>70185</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>March 17, 2014</study_first_submitted>
  <study_first_submitted_qc>March 18, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 20, 2014</study_first_posted>
  <last_update_submitted>August 27, 2019</last_update_submitted>
  <last_update_submitted_qc>August 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Örebro University, Sweden</investigator_affiliation>
    <investigator_full_name>Robert Brummer</investigator_full_name>
    <investigator_title>MD, PhD</investigator_title>
  </responsible_party>
  <keyword>Fecal transplantation</keyword>
  <keyword>microbiota transplantation</keyword>
  <keyword>irritable bowel syndrome</keyword>
  <keyword>IBS</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
    <mesh_term>Syndrome</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

